|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interferon-beta inhibits Toll-like receptor 9processing in multiple sclerosis显示文摘 | Konstantin E Latt L | 2010 | Ann Neurol2010，68，6： | 1 |
| 2 | Medial patellofemoral ligament (MPFL) reconstruction for the treatment of patel- lofemoral instability显示文摘 | Csintalan R P Latt L D Fornalski S | 2014 | J Knee Surg2014，27，2： | 1 |
| 3 | Early results show: Well Point' s Patient-Centered Medical Homepilots have met some goals for costs, utilization, and quality 显示文摘 | Raskas R S Latts L M Hummel J R | 2012 | Health Affairs2012，31，9： | 1 |
| 4 | 显示文摘 | Li S Dong Z L Maung Latt K | 2002 | Appl Phys Lett2002，80，13： | 1 |
| 5 | Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-na?ve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety显示文摘AIM To evaluate sustained viral response(SVR) of 8-wk ledipasvir/sofosbuvir therapy among non-cirrhotic, genotype-1 hepatitis C virus(HCV) patients with RNA < 6 million IU/m L.METHODS We performed a retrospective cohort study to examine SVR rates, predictors of treatment failure and safety analysis of 8-wk ledipasvir/sofosbuvir(LDV/SOF) therapy among non-cirrhotic, genotype 1 HCV patients with viral load < 6 million IU/m L. Primary outcome was an achievement of SVR at 12 wk after treatment. Secondary outcomes were identifying predictors of treatment failure and adverse events during treatment.RESULTS Total 736 patients: 55% males, 51% Caucasians and 65% were genotype 1a. Non-cirrhotic state of 53% was determined by clinical judgment(imaging, AST, platelet count) and 47% had documented liver fibrosis testing(biopsy, vibration-controlled transient elastography, serum biomarkers). Overall SVR12 was 96%. No difference in SVR12 was seen between patients whose non-cirrhotic state was determined by clinical judgment and patients who had fibrosis testing. Age groups, gender, ethnicity and genotype 1 subtype did not predict SVR. Non-cirrhotic state determined by clinical judgment based on simple, non-invasive tests were not associated with lower SVR [OR = 1.02, 95%CI: 0.48-2.17, P = 0.962]. The AUROC for hepatitis C RNA viral load was 0.734(P < 0.001, 95%CI: 0.66-0.82). HCV RNA 2.2 million IU/m L was identified as the cutoff value with sensitivity 73% and specificity 64%. HCV RNA < 2.2 million IU/m L was associated with significantly higher SVR 98% with OR = 0.22(95%CI: 0.1-0.49, P < 0.001) compared to SVR 92% in HCV RNA ≥ 2.2 million IU/m L. No death or morbidities were reported.CONCLUSION Our outcomes validate safety and effectiveness of 8-wk LDV/SOF therapy in non-cirrhotic, untreated HCV genotype 1 patients with HCV RNA < 6 million IU/m L. | Nyan L Latt Beshoy T Yanny Derenik Gharibian Rita Gevorkyan Amandeep K Sahota | 2017 | World Journal of Gastroenterology2017，23，26： | 1 |
| 6 | The impact of layer thickness of IMP-deposited tantalum nitride films on integrity of Cu/TaN/SiO2/Si multilayer structure显示文摘 | KHIN MAUNG LATT LEE Y K LI S OSIPOWICZ T SENG H L | 2001 | Materials Science and Engineering B2001，84，3： | 1 |
| 7 | Some two-echelon style-goods inventory models with asymmetric market information显示文摘 | Latt A H L | 2001 | European Journal of Operalional Research2001，134，： | 1 |
| 8 | Experimental validation of circumferential,longitudinal,and radial 2 -dimensional strain during dobutamine stress echocardiography in ischemic conditions显示文摘 | Reant P Labrousse L Latte S | 2008 | J Am Coll Cardiol2008，51，： | 1 |
| 9 | Expanding indications for liver transplantation in the era of liver transplant oncology显示文摘Despite numerous advances and emerging data,liver transplantation in the setting of gastrointestinal malignancies remains controversial outside of certain accepted indications.In an era of persistent organ shortage and increasing organ demand,allocation of liver grafts must be considered carefully.While hepatocellular carcinoma and hilar cholangiocarcinoma have become accepted indications for transplantation,tumor size and standardized multi-disciplinary treatment protocols are necessary to ensure optimal patient outcomes.As more studies seeking to expand the oncologic indications for liver transplantation are emerging,it is becoming increasingly clear that tumor biology and response to therapy are key factors for optimal oncologic outcomes.In addition,time from diagnosis to transplantation appears to correlate with survival,as stable disease over time portends better outcomes post-operatively.Identifying aggressive disease pre-transplant remains difficult with current imaging and tissue sampling techniques.While tumor size and stage are important prognostic predictors for most malignancies,patient and tumor selection protocols are necessary.As the fields of medical and surgical oncology continue to evolve,it is clear that a protocolized interdisciplinary treatment approach is necessary for combatting any cancer effectively.Disease stability over time and response to neoadjuvant therapy may be the best predictors for successful patient outcomes and can be easily incorporated in our treatment paradigms.Current data evaluating liver transplantation for expanded oncologic indications such as:expanded criteria hepatocellular carcinoma,intrahepatic cholangiocarcinoma,mixed tumors,and liver limited metastatic colorectal carcinomas,incorporate multi-modal therapies and evaluation of tumor treatment response.While further investigation is necessary,initial results suggest there is an expanded role for transplant surgery in malignancy in a new era of liver transplant oncology. | Guergana Panayotova Keri E Lunsford Nyan L Latt Flavio Paterno James V Guarrera Nikolaos Pyrsopoulos | 2021 | World Journal of Gastrointestinal Surgery2021，13，5： | 0 |
| 10 | Liver transplant allocation policies and outcomes in United States: A comprehensive review显示文摘Liver transplant allocation policies in the United States has evolved over 3 decades.The donor liver organs are matched,allocated and procured by the Organ Procurement and Transplantation Network which is administered by the United Network of Organ Sharing(UNOS),a not-for-profit organization governed by the United States human health services.We reviewed the evolution of liver transplant allocation policies.Prior to 2002,UNOS used Child-Turcotte-Pugh score to list and stratify patients for liver transplantation(LT).After 2002,UNOS changed its allocation policy based on model for end-stage liver disease(MELD)score.The serum sodium is the independent indicator of mortality risk in patients with chronic liver disease.The priority assignment of MELD-sodium score resulted in LT and prevented mortality on waitlist.MELD-Sodium score was implemented for liver allocation policy in 2016.Prior to the current and most recent policy,livers from adult donors were matched first to the status 1A/1B patients located within the boundaries of the UNOS regions and donor-service areas(DSA).We reviewed the disadvantages of the DSA-based allocation policies and the advantages of the newest acuity circle allocation model.We then reviewed the standard and non-standard indications for MELD exceptions and the decision-making process of the National Review Liver Review Board.Finally,we reviewed the liver transplant waitlist,donation and survival outcomes in the United States. | Nyan L Latt Mumtaz Niazi Nikolaos T Pyrsopoulos | 2022 | World Journal of Methodology2022，12，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员